{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:39:25Z","timestamp":1767987565752,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T00:00:00Z","timestamp":1428537600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1202-4","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T04:04:13Z","timestamp":1428465853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer"],"prefix":"10.1186","volume":"15","author":[{"given":"Masaru","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Seike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rintaro","family":"Noro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Soeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Miyanaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Gemma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,9]]},"reference":[{"key":"1202_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1202_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMoa003034","volume":"346","author":"K Noda","year":"2002","unstructured":"Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85\u201391.","journal-title":"N Engl J Med"},{"key":"1202_CR3","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129\u201339.","journal-title":"N Engl J Med"},{"key":"1202_CR4","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, J\u00e4nne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497\u2013500.","journal-title":"Science"},{"key":"1202_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561\u20136.","journal-title":"Nature"},{"key":"1202_CR6","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380\u20138.","journal-title":"N Engl J Med"},{"key":"1202_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121\u20138.","journal-title":"Lancet Oncol"},{"issue":"25","key":"1202_CR8","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K, Seto T, Crin\u00f3 L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385\u201394.","journal-title":"N Engl J Med"},{"issue":"9637","key":"1202_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449\u201356.","journal-title":"Lancet"},{"issue":"6","key":"1202_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514\u201323.","journal-title":"N Engl J Med"},{"issue":"6","key":"1202_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris 3rd HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"1202_CR12","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/sj.bjc.6605761","volume":"103","author":"K Schmid","year":"2010","unstructured":"Schmid K, Bago-Horvath Z, Berger W, Haitel A, Cejka D, Werzowa J, et al. Dual inhibition of EGFR and mTOR pathway in small cell lung cancer. Br J Cancer. 2010;103(5):622\u20138.","journal-title":"Br J Cancer"},{"issue":"23","key":"1202_CR13","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1158\/1078-0432.CCR-10-0802","volume":"16","author":"A Tarhini","year":"2010","unstructured":"Tarhini A, Kotsakis A, Gooding W, Shuai Y, Petro D, Friedland D, et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res. 2010;16(23):5900\u20137.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1202_CR14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/annonc\/mdt535","volume":"25","author":"B Besse","year":"2014","unstructured":"Besse B, Heist RS, Papadmitrakopoulou VA, Camidge DR, Beck JT, Schmid P, et al. A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. Ann Oncol. 2014;25(2):505\u201311.","journal-title":"Ann Oncol"},{"issue":"6","key":"1202_CR15","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/bjc.2013.467","volume":"109","author":"JM Sun","year":"2013","unstructured":"Sun JM, Kim JR, Do IG, Lee SY, Lee J, Choi YL, et al. A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer. Br J Cancer. 2013;109(6):1482\u20137.","journal-title":"Br J Cancer"},{"issue":"2","key":"1202_CR16","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/1535-7163.MCT-13-0448","volume":"13","author":"K Kitamura","year":"2014","unstructured":"Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, et al. MiR-134\/487b\/655 cluster regulates TGF-\u03b2-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther. 2014;13(2):444\u201353.","journal-title":"Mol Cancer Ther"},{"key":"1202_CR17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/jnci\/djm083","volume":"99","author":"M Seike","year":"2007","unstructured":"Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst. 2007;99:1257\u201369.","journal-title":"J Natl Cancer Inst"},{"key":"1202_CR18","doi-asserted-by":"publisher","first-page":"12085","DOI":"10.1073\/pnas.0905234106","volume":"106","author":"M Seike","year":"2009","unstructured":"Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Horikawa I, et al. MiR-21is an EGFR-regulated anti-apoptonic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A. 2009;106:12085\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1202_CR19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/bjc.2012.7","volume":"106","author":"T Shimokawa","year":"2012","unstructured":"Shimokawa T, Seike M, Soeno C, Uesaka H, Miyanaga A, Mizutani H, et al. Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules. Br J Cancer. 2012;106:867\u201375.","journal-title":"Br J Cancer"},{"issue":"6","key":"1202_CR20","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3892\/ijo.2014.2370","volume":"44","author":"S Takeuchi","year":"2014","unstructured":"Takeuchi S, Seike M, Noro R, Soeno C, Sugano T, Zou F, et al. Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed. Int J Oncol. 2014;44(6):1886\u201394.","journal-title":"Int J Oncol"},{"key":"1202_CR21","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/onc.2009.478","volume":"29","author":"K Tajima","year":"2010","unstructured":"Tajima K, Ohashi R, Sekido Y, Hida T, Nara T, Hashimoto M, et al. Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene. 2010;29:1941\u201351.","journal-title":"Oncogene"},{"issue":"37","key":"1202_CR22","doi-asserted-by":"publisher","first-page":"E699","DOI":"10.1073\/pnas.1108237108","volume":"108","author":"N Ilic","year":"2011","unstructured":"Ilic N, Utermark T, Widlund HR, Roberts TM. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A. 2011;108(37):E699\u2013708.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1202_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cell.2012.08.033","volume":"151","author":"Z Nie","year":"2012","unstructured":"Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151(1):68\u201379.","journal-title":"Cell"},{"key":"1202_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/jcb.240630516","volume":"24","author":"BE Johnson","year":"1996","unstructured":"Johnson BE, Russell E, Simmons AM, Phelps R, Steinberg SM, Ihde DC, et al. MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer. J Cell Biochem Suppl. 1996;24:210\u20137.","journal-title":"J Cell Biochem Suppl"},{"issue":"18","key":"1202_CR25","first-page":"5163","volume":"48","author":"BE Johnson","year":"1988","unstructured":"Johnson BE, Makuch RW, Simmons AD, Gazdar AF, Burch D, Cashell AW. Myc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines. Cancer Res. 1988;48(18):5163\u20136.","journal-title":"Cancer Res"},{"issue":"10","key":"1202_CR26","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1586\/14737140.8.10.1689","volume":"8","author":"Y Chen","year":"2008","unstructured":"Chen Y, Olopade OI. MYC in breast tumor progression. Expert Rev Anticancer Ther. 2008;8(10):1689\u201398.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"1202_CR27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/BF02303778","volume":"5","author":"DL Sorrells","year":"1998","unstructured":"Sorrells DL, Black DR, Meschonat C, Rhoads R, De Benedetti A, Gao M, et al. Detection of eIF4E gene amplification in breast cancer by competitive PCR. Ann Surg Oncol. 1998;5(3):232\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1202_CR28","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1158\/1535-7163.MCT-11-0184","volume":"11","author":"KE Hook","year":"2012","unstructured":"Hook KE, Garza SJ, Lira ME, Ching KA, Lee NV, Cao J, et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther. 2012;11(3):710\u20139.","journal-title":"Mol Cancer Ther"},{"key":"1202_CR29","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1158\/1535-7163.MCT-08-0857","volume":"8","author":"X Shang","year":"2009","unstructured":"Shang X, Burlingame SM, Okcu MF, Ge N, Russell HV, Egler RA, et al. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther. 2009;8:2461\u20139.","journal-title":"Mol Cancer Ther"},{"key":"1202_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ccr.2008.12.005","volume":"15","author":"T Otto","year":"2009","unstructured":"Otto T, Horn S, Brockmann M, Eilers U, Sch\u00fcttrumpf L, Popov N, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2009;15:67\u201378.","journal-title":"Cancer Cell"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1202-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1202-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1202-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1202-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T10:12:00Z","timestamp":1630577520000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1202-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,9]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1202-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,9]]},"assertion":[{"value":"6 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"241"}}